Hormone

Healthed
Learning Modules iconLearning Modules

This course is aimed at helping clinicians maximise the effectiveness of MHT while minimising the potential risks across a range of circumstances and scenarios. The most effective treatment for troublesome symptoms of menopause is still hormone therapy. Body identical hormones are now available which offer a number of clinical advantages. Moreover, drug delivery options are also varied – patch, pill, gel, etc. so clinicians can work with patients to determine which hormones and which delivery system is best suited to their needs.

Expert/s: Healthed
Dr Terri Foran (Facilitator) and experts Prof Susan Davis AO, A/Prof John Eden, Dr Rosie King
Podcasts iconPodcasts

Conversation is important to the diagnosis- anything and everything can impact sexual response.

Fiona Clark
Clinical Articles iconClinical Articles

Australia is the only country to have a licensed testosterone product for women, but prescribing it is still controversial

Expert/s: Fiona Clark
Healthed
Learning Modules iconLearning Modules

For many years it has been mooted that not all menopausal symptoms are caused by lack of oestrogen alone. Testosterone therapy in women has been proven to improve sexual desire in carefully selected patients. It is a valid treatment in those who are distressed by their lack of sexual desire where there is no other cause obvious for this. How, what, where and in whom are the challenges faced by treating clinicians. In this learning module, some of Australia's leading experts will discuss the evidence, describe their clinical experience and provide practical advice on how best to apply this emerging therapeutic option.

Expert/s: Healthed
Dr Terri Foran
Videos iconVideos

In this Product Explainer, Sexual Health Physician Dr Terri Foran explains estradiol and progesterone combined hormone therapy, the first and only body-identical combined treatment for post-menopausal women (6 mins).

Expert/s: Dr Terri Foran
Dr Linda Calabresi
Clinical Articles iconClinical Articles

No longer is it okay to just monitor a patient with mild hyperparathyroidism as research shows the untreated condition is associated with a significantly increased risk of cardiovascular death